Supernus Pharma: (NASD: SUPN)
$6.00
0.16 (2.74%)
Volume 927,579
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 5.81 - 6.09 |
| 52wk Low - High | 4.30 - 16.68 |
| Previous Close | 5.84 |
| Avg. Volume | 770,277 |
| Industry | MED-GENERIC DRG |
| Market Cap | 185.35 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.19 |
| PE (Forward) | 0.00 |
| Current Year Est. | -2.59 |
| Quarterly Earnings ESP |
5.63% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
234 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -2.59 |
| Current Quarter Estimate | -0.71 |
| Most Accurate Estimate | -0.67 |
| Earnings ESP |
5.63% |
| Next Earnings Report Date | 08-09-2013 |
| EPS Last Year | -2.27 |
| Expected Earnings Growth | NA |
Company Description
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.71 | -0.70 | -2.59 | -1.09 |
| Number of Estimates | 2 | 2 | 3 | 2 |
| Low Estimate | -0.74 | -0.72 | -2.87 | -1.37 |
| High Estimate | -0.67 | -0.67 | -2.32 | NA |
| Year Ago EPS | -0.61 | -0.55 | -2.72 | -2.59 |
| EPS Growth | -15.57% | -26.36% | 4.78% | 57.92% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| SUPERNUS PHARMA | SUPN | 6.00 | |
|
| ACTAVIS INC | ACT | 125.50 | |
|
| ACURA PHARMACT | ACUR | 2.35 | |
|
| HI TECH PHARMA | HITK | 32.27 | |
|
| IMPAX LABORATRS | IPXL | 18.42 | |
|
| KALOBIOS PHARMA | KBIO | 5.82 | |
|
| MYLAN INC | MYL | 31.40 | |
|
| OMTHERA PHARMA | OMTH | 7.08 | |
|
| SIMCERE PHARMAC | SCR | 9.26 | |
|
| TEVA PHARM ADR | TEVA | 40.23 | |
|
Sector:Medical>> Industry:MED-GENERIC DRG
COMPARE TICKER vs. Its Peers
Zacks Commentary
Narrower-than-Expected Loss at Supernus
May 14, 2013
Bearish MACD for Supernus Pharmaceuticals Inc.
Apr 23, 2013
Loss Narrows at Supernus
Mar 15, 2013
Supernus' Update on Oxtellar
Feb 08, 2013
Oxtellar XR Launched by Supernus
Feb 05, 2013
Pipeline Advances at Supernus
Nov 26, 2012
Report for SUPN
May 10, 2013
Financials
| EPS TTM | -2.27 |
| Sales | 1 |
| Net Income | -55 |
| Price/Earnings | NA |
| Price/Book | 3.18 |
| Price/Cash Flow | NA |
| Price/Sales | 130.62 |
News
8 Stocks Under $10 Trending Sharply Higher - TheStreet.com
May 14, 2013
Supernus Pharmaceuticals IncCorporate Event Announcement Notice - Wall Street Horizon
May 14, 2013
Supernus Pharmaceuticals IncCorporate Event Announcement Notice - Wall Street Horizon
May 13, 2013
Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results - Globenewswire
May 13, 2013
Supernus Pharmaceuticals Inc closes private offering of USD90m convertible senior secured notes - M2
May 7, 2013
Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019 - Globenewswire
May 6, 2013
Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast - Globenewswire
May 6, 2013
Supernus Pharmaceuticals IncCorporate Event Announcement Notice - Wall Street Horizon
May 6, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 5 |
| Average Target Price | 12.00 |
| Industry Rank by ABR | 234 out of 265 |
| Rank in Industry | 1 out of 13 |
